Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ENPP3 | O14638 | 9/20 | 0.65 |
| ▸ | ENPP1 | P22413 | 8/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125695 | 0.82 | PTPN1 (0.89) | LMNAENPP3ENPP1SMN1; SMN2NPSR1 | |
| SCHEMBL28656982 | 0.82 | PTPN1 (0.89) | LMNAENPP3ENPP1SMN1; SMN2NPSR1 | |
| SCHEMBL2874980 | 0.81 | LMNA (0.60) | LMNAENPP3ENPP1HTTSMN1; SMN2 | |
| SCHEMBL1339196 | 0.80 | PTPN1 (0.71) | LMNAENPP3ENPP1NPSR1KMT2A | |
| Hydrochloric Acid SCHEMBL31148097 | 0.79 | ULK1 (0.50) | LMNAENPP3ENPP1HTTSMN1; SMN2 | |
| SCHEMBL8363734 | 0.78 | PTPN1 (0.74) | LMNAENPP3ENPP1NPSR1KMT2A | |
| SCHEMBL13105759 | 0.78 | PTPN1 (0.74) | LMNAENPP3ENPP1HTTSMN1; SMN2 | |
| SCHEMBL933462 | 0.77 | ALDH1A1 (0.59) | SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL12793783 | 0.77 | CA12 (0.72) | SMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL16589431 | 0.77 | ALDH1A1 (0.68) | LMNAENPP3ENPP1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | LMNA 3732/4885ENPP3 1472/4885ENPP1 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.